Medical College, Soochow University, Suzhou, China.
Department of Otolaryngology, Otolaryngology & Head and Neck Center, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
J Clin Lab Anal. 2022 Nov;36(11):e24729. doi: 10.1002/jcla.24729. Epub 2022 Oct 25.
This study intends to use artificial microRNA (recombinant adenovirus vector) targeting epidermal growth factor receptor (EGFR) to inhibit the overexpressed EGFR in nasopharyngeal carcinoma, thereby inhibiting the proliferation and metastasis of nasopharyngeal carcinoma.
The research group verified the expression of EGFR in nasopharyngeal carcinoma through databases, clinical tissues, and cellular pathways. The team first tested the transfection of the recombinant adenovirus by fluorescence microscopy. After adenovirus treatment with different multiplicity of infection (MOI), EGFR level and cell viability in cells were examined by Western blot and MTT assay. Next, the effects of adenovirus (Ad)-SLPI-EGFR on cell proliferation, migration, apoptosis, and related proteins were sequentially examined by EdU, scratch, Transwell, and Western blot. In vivo experiments were performed to evaluate the biological function of EGFR in nasopharyngeal carcinoma.
All three validation pathways showed the increase in EGFR expression in nasopharyngeal carcinoma. Transfection tests showed that the SLPI promoter was specific in CNE2 cells. With the increase in MOI, the inhibition of EGFR expression and cancer cell viability by Ad-SLPI-EGFR was enhanced. Meanwhile, Ad-SLPI-EGFR effectively reduced the proliferation and metastasis of CNE2 cells and affected the expression of related proteins. Furthermore, Ad-SLPI-EGFR inhibited the invasion and metastasis of nasopharyngeal carcinoma in vivo.
Ad-SLPI-EGFR inhibits the expression of EGFR in nasopharyngeal carcinoma cells, and finally achieves the purpose of inhibiting the proliferation and metastasis of cancer cells, which may provide novel targeted intervention for the treatment of nasopharyngeal carcinoma.
本研究旨在利用靶向表皮生长因子受体（EGFR）的人工 microRNA（重组腺病毒载体）抑制鼻咽癌细胞中过表达的 EGFR，从而抑制鼻咽癌细胞的增殖和转移。
研究小组通过数据库、临床组织和细胞通路验证了鼻咽癌中 EGFR 的表达。研究小组首先通过荧光显微镜验证重组腺病毒的转染。在用不同感染复数（MOI）处理腺病毒后，通过 Western blot 和 MTT 检测细胞中 EGFR 水平和细胞活力。然后，通过 EdU、划痕、Transwell 和 Western blot 依次检测腺病毒（Ad）-SLPI-EGFR 对细胞增殖、迁移、凋亡和相关蛋白的影响。进行体内实验以评估 EGFR 在鼻咽癌中的生物学功能。
所有三种验证途径均显示出鼻咽癌中 EGFR 表达增加。转染试验表明，SLPI 启动子在 CNE2 细胞中具有特异性。随着 MOI 的增加，Ad-SLPI-EGFR 对 EGFR 表达和癌细胞活力的抑制作用增强。同时，Ad-SLPI-EGFR 有效降低了 CNE2 细胞的增殖和转移，并影响了相关蛋白的表达。此外，Ad-SLPI-EGFR 抑制了鼻咽癌的体内侵袭和转移。
Ad-SLPI-EGFR 抑制鼻咽癌细胞中 EGFR 的表达，最终达到抑制癌细胞增殖和转移的目的，这可能为鼻咽癌的治疗提供新的靶向干预策略。
